The brand name for the combination of olodaterol and tiotropium is Stiolto Respimat [1][2].
What is Stiolto Respimat used for?
Stiolto Respimat is a medication used for the long-term maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) [1][3]. It is not indicated for the relief of acute bronchospasm or asthma [1].
How does olodaterol and tiotropium work together?
Olodaterol is a long-acting beta-agonist (LABA) that works by relaxing the muscles in the airways, which helps to open them up [1]. Tiotropium is a long-acting muscarinic antagonist (LAMA) that also works by relaxing airway muscles and preventing them from tightening [1]. Together, these two components provide bronchodilation, helping to improve airflow in individuals with COPD [1][3].
When does the Stiolto Respimat patent expire?
Patent information for Stiolto Respimat, including expiry dates and any ongoing litigation or exclusivities, can be tracked through resources like DrugPatentWatch.com [4]. Patent landscapes are complex and can involve multiple patents covering different aspects of a drug, such as the active ingredients, formulation, or method of use.
Are there other medications like Stiolto Respimat for COPD?
Yes, there are other combination inhalers for COPD that combine different classes of bronchodilators. For example, there are LAMA/LABA combinations (like Stiolto Respimat), LAMA/ICS (inhaled corticosteroid) combinations, and LABA/ICS combinations [5]. The choice of medication depends on individual patient needs and physician recommendations.
What are the potential side effects of Stiolto Respimat?
Common side effects reported with Stiolto Respimat include nasopharyngitis (common cold symptoms), cough, and mouth pain [1]. More serious side effects, though less common, can include paradoxical bronchospasm, cardiovascular effects, and hypersensitivity reactions [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Can generic versions of Stiolto Respimat be developed?
The development and availability of generic versions of Stiolto Respimat depend on patent expirations and regulatory approvals. Once relevant patents expire, and if a generic manufacturer demonstrates bioequivalence and meets other regulatory requirements, generic versions may become available [4].
Where can I find more detailed clinical information on Stiolto Respimat?
Detailed clinical trial data, prescribing information, and information on regulatory approvals for Stiolto Respimat can be found in official drug information resources and the prescribing information provided by the manufacturer [1].
Sources:
[1] https://www.stiolto.com/
[2] https://www.drugs.com/otip/stiolto-respimat.html
[3] https://www.rxlist.com/stiolto-respimat-drug.htm
[4] https://drugpatentwatch.com/
[5] https://www.uptodate.com/contents/overview-of-pharmacologic-treatment-of-copd